Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.

G. Willemoe,P. B. Hertel,Annette Bartels,M. Jensen,E. Balslev,B. Rasmussen,H. Mouridsen,B. Ejlertsen,N. Brünner
DOI: https://doi.org/10.1016/j.ejca.2009.05.029
IF: 10.002
2009-09-01
European Journal of Cancer
Abstract:
What problem does this paper attempt to address?